Using Biological Definitions to Improve Drug Development for Parkinson's Disease
Author Information
Author(s): Gennaro Pagano, Tien Dam, Geoffrey A. Kerchner, Wendy R. Galpern, Milton Biagioni, Rajesh Karan, Danna Jennings, M. Judith Peterschmitt, Tania Nikolcheva, Patrik Brundin
Primary Institution: Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Hypothesis
Can biologically defined populations improve the precision of treatments for synucleinopathies?
Conclusion
Biologically defined frameworks for synucleinopathies can enhance drug development by targeting specific populations with tailored treatments.
Supporting Evidence
- Biological definitions can help target treatments more precisely.
- Current biomarkers for synucleinopathies are often not accessible to all patients.
- Staging systems can improve the design of clinical trials for neurodegenerative diseases.
Takeaway
This study suggests that using biological markers to define diseases like Parkinson's can help doctors find the right treatments for the right patients faster.
Potential Biases
Potential inequities in healthcare access may affect the implementation of these biomarkers.
Limitations
Current biomarkers are not widely accessible or affordable, and some require invasive procedures.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website